Detection and interpretation of altered methylation patterns in cancer cells
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Epigenetic alterations, such as abnormal DNA-methylation patterns, are associated with many human tumour types. New techniques have been developed to perform genome-wide screening for alterations in DNA-methylation patterns, not only to identify tumour-suppressor genes, but also to find patterns that can be used in diagnosis and prognosis. However, interpretation of differential methylation has proven difficult because the significance of methylation alterations depends on the genomic region, and functions of CpG islands at specific sites have not been fully clarified. What techniques can be used to identify new tumour suppressors and diagnostic markers?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ROS influence the activity of epigenetic modulators, such as histone deacetylases (HDACs) or DNA methyltransferases (DNMTs) with consequences that are evident in the expression of the target genes38,39.”
From ROS in cancer therapy: the bright side of the moon (2020) · cites this paper as [39]
Citations
Cites
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
CpG Islands in vertebrate genomes
Gardiner-Garden, M., & Frommer, M. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90689-9 · Cited by 3,353
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
CpG island methylator phenotype in colorectal cancer
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J.-P. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8681 · Cited by 2,523
Hypomethylation distinguishes genes of some human cancers from their normal counterparts
Feinberg, A. P., & Vogelstein, B. (1983) · Nature · doi:10.1038/301089a0 · Cited by 2,437
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene
Bell, A. C., & Felsenfeld, G. (2000) · Nature · doi:10.1038/35013100 · Cited by 1,746 · cited 1×
“), and defines regions for transcriptional regulatio”
Cited by
ROS in cancer therapy: the bright side of the moon
Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G., & Migliaccio, A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0384-2 · Cited by 2,176
Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?
Baylin, S. B., & Ohm, J. E. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1799 · Cited by 1,639
Principles and challenges of genome-wide DNA methylation analysis
Laird, P. W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2732 · Cited by 1,572
Reactive oxygen species and cancer paradox: To promote or to suppress?
Galadari, S., Rahman, A., Pallichankandy, S., & Thayyullathil, F. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.004 · Cited by 893
Dynamic DNA methylation across diverse human cell lines and tissues
Varley, K. E., Gertz, J., Bowling, K. M., Parker, S. L., Reddy, T. E., Pauli-Behn, F., Cross, M. K., Williams, B. A., Stamatoyannopoulos, J. A., Crawford, G. E., et al. (2013) · Genome Research · doi:10.1101/gr.147942.112 · Cited by 704
“…differentiation (Lei et al. 1996; Okano et al. 1999; Jackson et al. 2004; Blelloch et al. 2006; Ji et al. 2010; Kim et al. 2010), and disease, including cancer where vast changes in DNA methylation patterns occur (Laird and Jaenisch 1994; Ushijima 2005; Sharma et al. 2010; Tsai and Baylin 2011).”
BackgroundMaekita, T., Nakazawa, K., Mihara, M., Nakajima, T., Yanaoka, K., Iguchi, M., Arii, K., Kaneda, A., Tsukamoto, T., Tatematsu, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2096 · Cited by 639
Self-citationReactive Oxygen Species (ROS)––Induced genetic and epigenetic alterations in human carcinogenesis
Ziech, D., Franco, R., Pappa, A., & Panayiotidis, M. I. (2011) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2011.02.015 · Cited by 568
Distinct epigenetic changes in the stromal cells of breast cancers
Hu, M., Yao, J., Cai, L., Bachman, K. E., van den Brûle, F., Velculescu, V., & Polyak, K. (2005) · Nature Genetics · doi:10.1038/ng1596 · Cited by 520
Chan, K. C. A., Jiang, P., Chan, C. W. M., Sun, K., Wong, J., Hui, E. P., Chan, S. L., Chan, W. C., Hui, D. S. C., Ng, S. S. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313995110 · Cited by 447
Taby, R., & Issa, J.-P. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20085 · Cited by 407
The cancer epigenome—components and functional correlates
Ting, A. H., McGarvey, K. M., & Baylin, S. B. (2006) · Genes & Development · doi:10.1101/gad.1464906 · Cited by 419
“Most recently, studies of hypermethylated genes identified by emerging techniques to screen cancer cell genomes for epigenetic changes (Ushijima 2005) are revealing a potential network of epigenetic events that, again, stress the theme that epigenetic alterations may have pivotal involvement in…”
BackgroundFrigola, J., Song, J., Stirzaker, C., Hinshelwood, R. A., Peinado, M. A., & Clark, S. J. (2006) · Nature Genetics · doi:10.1038/ng1781 · Cited by 409
Comparative isoschizomer profiling of cytosine methylation: The HELP assay
Khulan, B., Thompson, R. F., Ye, K., Fazzari, M. J., Suzuki, M., Stasiek, E., Figueroa, M. E., Glass, J. L., Chen, Q., Montagna, C., et al. (2006) · Genome Research · doi:10.1101/gr.5273806 · Cited by 396
“This topic has been extensively reviewed (Laird 2003; Ushijima 2005) prior to the recent publication of several new approaches (Ching et al.”
BackgroundMethodFuchikami, M., Morinobu, S., Segawa, M., Okamoto, Y., Yamawaki, S., Ozaki, N., Inoue, T., Kusumi, I., Koyama, T., Tsuchiyama, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023881 · Cited by 378
“However, it is not necessary that DNA methylation markers for diseases always induces gene silencing [19].”
BackgroundEpigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors
Herceg, Z. (2007) · Mutagenesis · doi:10.1093/mutage/gel068 · Cited by 374
Comparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer
Schuebel, K. E., Chen, W., Cope, L., Glöckner, S. C., Suzuki, H., Yi, J.-M., Chan, T. A., Neste, L. V., Criekinge, W. V., Bosch, S. V. D., et al. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030157 · Cited by 347
“The exact number of such epigenetic lesions in any given tumor is not precisely known, although a growing number of screening approaches, none covering the whole genome efficiently, are identifying an increasing number of candidate genes [5–13].”
BackgroundHigh-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer
Rauch, T. A., Zhong, X., Wu, X., Wang, M., Kernstine, K. H., Wang, Z., Riggs, A. D., & Pfeifer, G. P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710735105 · Cited by 318
Tost, J. (2010) · Molecular Biotechnology · doi:10.1007/s12033-009-9216-2 · Cited by 296
Rauch, T., Li, H., Wu, X., & Pfeifer, G. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1888 · Cited by 292
Rauch, T., Wang, Z., Zhang, X., Zhong, X., Wu, X., Lau, S. K., Kernstine, K. H., Riggs, A. D., & Pfeifer, G. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701059104 · Cited by 287
Nishida, N., Nagasaka, T., Nishimura, T., Ikai, I., Boland, R. C., & Goel, A. (2008) · Hepatology · doi:10.1002/hep.22110 · Cited by 286
“Methylation of group 1 loci were significantly higher in HCV-related HCC than in virus-negative (A) [ANOVA; F(2, 522) 4.”
BackgroundInfluentialLoss of 5‐hydroxymethylcytosine is accompanied with malignant cellular transformation
Kudo, Y., Tateishi, K., Yamamoto, K., Yamamoto, S., Asaoka, Y., Ijichi, H., Nagae, G., Yoshida, H., Aburatani, H., & Koike, K. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02213.x · Cited by 278
Genome-wide analysis of DNA methylation patterns
Zilberman, D., & Henikoff, S. (2007) · Development · doi:10.1242/dev.001131 · Cited by 275
“Many methods of DNA methylation analysis have been developed over the years and are described in detail in a number of recent reviews (Brena et al., 2006; Callinan and Feinberg, 2006; Laird, 2003; Lieb et al., 2006; Ushijima, 2005).”
MethodOgino, S., Kawasaki, T., Nosho, K., Ohnishi, M., Suemoto, Y., Kirkner, G. J., & Fuchs, C. S. (2008) · International Journal of Cancer · doi:10.1002/ijc.23470 · Cited by 261
“Epigenomic aberrations are important mechanisms in human carcinogenesis.(1,2) A number of tumor suppressor genes are”
BackgroundOn the Stem Cell Origin of Cancer
Sell, S. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091064 · Cited by 257
“cells that continue to give rise to hypermethylated transitamplifying cells.(102)”
BackgroundYamashita, S., Tsujino, Y., Moriguchi, K., Tatematsu, M., & Ushijima, T. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00136.x · Cited by 253
Self-citationEpigenetic Field for Cancerization
Ushijima, T. (2007) · BMB Reports · doi:10.5483/bmbrep.2007.40.2.142 · Cited by 248
“Even when methylation of a gene body is associated with decreased transcription, such association has many exceptions, and does not have a causal role in gene silencing (Ushijima, 2005).”
BackgroundInfluentialSelf-citationThree DNA Methylation Epigenotypes in Human Colorectal Cancer
Yagi, K., Akagi, K., Hayashi, H., Nagae, G., Tsuji, S., Isagawa, T., Midorikawa, Y., Nishimura, Y., Sakamoto, H., Seto, Y., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2006 · Cited by 223
“Several approaches to detect aberrantly methylated regions in cancer have been developed, although most of these methods utilize methylation-sensitive restriction enzymes and thus only limited regions of genome can be analyzed (13).”
Tamura, G. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i2.192 · Cited by 222
Kanai, Y., & Hirohashi, S. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm206 · Cited by 220
DNA methylation methods: Global DNA methylation and methylomic analyses
Li, S., & Tollefsbol, T. O. (2021) · Methods · doi:10.1016/j.ymeth.2020.10.002 · Cited by 214
DNA Methylation Alterations in the Pancreatic Juice of Patients with Suspected Pancreatic Disease
Matsubayashi, H., Canto, M., Sato, N., Klein, A., Abe, T., Yamashita, K., Yeo, C. J., Kalloo, A., Hruban, R., & Goggins, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2664 · Cited by 212
“Most studies have found that cancer-specific methylation is usually located in this region (50).”
BackgroundDNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment
Barton, C. A., Hacker, N. F., Clark, S. J., & O'Brien, P. M. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.12.017 · Cited by 200
CpG Island Mapping by Epigenome Prediction
Bock, C., Walter, J., Paulsen, M., & Lengauer, T. (2007) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030110 · Cited by 191
“to our understanding of the epigenetic causes of cancer [15].”
BackgroundAberrant methylations in cancer cells: Where do they come from?
Ushijima, T., & Okochi‐Takada, E. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00035.x · Cited by 185
Self-citationYamaguchi, K., Mandai, M., Oura, T., Matsumura, N., Hamanishi, J., Baba, T., Matsui, S., Murphy, S. K., & Konishi, I. (2010) · Oncogene · doi:10.1038/onc.2009.470 · Cited by 184
Do Myoepithelial Cells Hold the Key for Breast Tumor Progression?
Polyak, K., & Hu, M. (2005) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-005-9584-6 · Cited by 180
“Consistent with prior results, increased DNA methylation in the promoter region of the genes negatively correlated with gene expression, while hypermethylation of introns and 3’ exons positively influenced gene expression suggesting the presence of silencer elements that are regulated by DNA methylation (79, 80).”
ResultIdentification of regions correlating MGMT promoter methylation and gene expression in glioblastomas
Everhard, S., Tost, J., El Abdalaoui, H., Crinière, E., Busato, F., Marie, Y., Gut, I. G., Sanson, M., Mokhtari, K., Laigle-Donadey, F., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-001 · Cited by 177
Lambert, M.-P., Paliwal, A., Vaissière, T., Chemin, I., Zoulim, F., Tommasino, M., Hainaut, P., Sylla, B., Scoazec, J.-Y., Tost, J., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.027 · Cited by 173
“In order to investigate the methylation level of several genes, targeted sequences were localized in bona fide CpG islands [25,26] (Supplementary Fig.”
BackgroundFuruta, J., Nobeyama, Y., Umebayashi, Y., Otsuka, F., Kikuchi, K., & Ushijima, T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0157 · Cited by 173
Self-citationEpigenetic regulation of Nanog gene in embryonic stem and trophoblast stem cells
Hattori, N., Imao, Y., Nishino, K., Hattori, N., Ohgane, J., Yagi, S., Tanaka, S., & Shiota, K. (2007) · Genes to Cells · doi:10.1111/j.1365-2443.2007.01058.x · Cited by 170
“Furthermore, epigenetic abnormality is one of the major causes of tumorigenesis (Robertson 2005; Ushijima 2005), and especially interesting is that cancer stem cells have been characterized by the expressions of Oct-4 and Nanog (Monk & Holding 2001; Ezeh et al.”
BackgroundInfluentialThe Bone Morphogenetic Protein Pathway Is Inactivated in the Majority of Sporadic Colorectal Cancers
Kodach, L. L., Wiercinska, E., de Miranda, N. F. C. C., Bleuming, S. A., Musler, A. R., Peppelenbosch, M. P., Dekker, E., van den Brink, G. R., van Noesel, C. J. M., Morreau, H., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.059 · Cited by 168
A Nanocarbon Film Electrode as a Platform for Exploring DNA Methylation
Kato, D., Sekioka, N., Ueda, A., Kurita, R., Hirono, S., Suzuki, K., & Niwa, O. (2008) · Journal of the American Chemical Society · doi:10.1021/ja710536p · Cited by 165
Yagi, S., Hirabayashi, K., Sato, S., Li, W., Takahashi, Y., Hirakawa, T., Wu, G., Hattori, N., Hattori, N., Ohgane, J., et al. (2008) · Genome Research · doi:10.1101/gr.074070.107 · Cited by 161
“Abnormal methylation of T-DMRs has been implicated in the pathogenesis of certain diseases (Jones 2002; Ushijima 2005).”
BackgroundDNA methylation biomarkers in cancer: progress towards clinical implementation
Mikeska, T., Bock, C., Do, H., & Dobrovic, A. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.45 · Cited by 161
Allegrucci, C., Wu, Y.-Z., Thurston, A., Denning, C. N., Priddle, H., Mummery, C. L., Ward-van Oostwaard, D., Andrews, P. W., Stojkovic, M., Smith, N., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm074 · Cited by 158
“Moreover, since initial methylation of isolated CpGs can lead to spreading in the surrounding regions over time (28), the possibility of later methylation changes affecting gene expression cannot be excluded.”
BackgroundKubota, T., Miyake, K., & Hirasawa, T. (2012) · Clinical Epigenetics · doi:10.1186/1868-7083-4-1 · Cited by 157
“Epigenetic alterations are seen in various cancers, and are currently used clinically as diagnostic markers [44].”
BackgroundNuclear microenvironments in biological control and cancer
Zaidi, S. K., Young, D. W., Javed, A., Pratap, J., Montecino, M. A., van Wijnen, A. J., Lian, J. B., Stein, J. L., & Stein, G. S. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2149 · Cited by 158
Prognostic DNA Methylation Biomarkers in Ovarian Cancer
Wei, S. H., Balch, C., Paik, H. H.-I., Kim, Y.-S., Baldwin, R. L., Liyanarachchi, S., Li, L., Wang, Z., Wan, J. C., Davuluri, R. V., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1551 · Cited by 164
DNA methylation biomarkers for lung cancer
Rauch, T. A., Wang, Z., Wu, X., Kernstine, K. H., Riggs, A. D., & Pfeifer, G. P. (2011) · Tumor Biology · doi:10.1007/s13277-011-0282-2 · Cited by 178
“Detection of methylated CpG islands in accessible biological materials such as serum or sputum has the recognized potential to be useful for the early detection and diagnosis of cancer, including lung cancer [3, 25, 43].”
BackgroundYu, J. Q., Tao, Q., Cheung, K. F., Jin, H., Poon, F. F., Wang, X., Li, H., Cheng, Y. Y., Röcken, C., Ebert, M. P. A., et al. (2008) · Hepatology · doi:10.1002/hep.22343 · Cited by 154
Noer, A., Sørensen, A. L., Boquest, A. C., & Collas, P. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-04-0322 · Cited by 159
“Mosaic methylation may result from stochastic methylation, which accumulates independently in different cells (CpG-rich sites are unmethylated at birth; Bird, 2002) as a result of exposure to environmental, aging, and health factors (Esteller, 2005; Hoffman and Carpenter, 2005; Laird, 2005; Ushijima, 2005; Zardo et al…”
Diagnostic and Therapeutic Applications of Epigenetics
Miyamoto, K., & Ushijima, T. (2005) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyi088 · Cited by 150
Self-citationDNA Methylation as a Molecular Biomarker in Gastric Cancer
Tahara, T., & Arisawa, T. (2015) · Epigenomics · doi:10.2217/epi.15.4 · Cited by 162
DNA methylation as a marker for the past and future
Ushijima, T., Nakajima, T., & Maekita, T. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1846-6 · Cited by 147
Self-citationWatanabe, Y., & Maekawa, M. (2010) · Advances in clinical chemistry · doi:10.1016/s0065-2423(10)52006-7 · Cited by 155
Identification of Driver and Passenger DNA Methylation in Cancer by Epigenomic Analysis
Kalari, S. K., & Pfeifer, G. P. (2010) · Advances in genetics · doi:10.1016/b978-0-12-380866-0.60010-1 · Cited by 158
“Global DNA hypomethylation and gene-specific hypermethylation are among the prominent hallmarks of cancer genomes (Ehrlich, 2002; Ushijima, 2005).”
Yoda, Y., Takeshima, H., Niwa, T., Kim, J. G., Ando, T., Kushima, R., Sugiyama, T., Katai, H., Noshirο, H., & Ushijima, T. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0348-0 · Cited by 156
“DNA methylation of a CGI in a promoter region, especially in the 200-bp upstream region from a transcription start site (TSS) (TSS200), is known to consistently silence its downstream gene, whereas that of downstream exons is weakly associated with increased expression [1, 26–28].”
BackgroundSelf-citationGenome-wide profiling of promoter methylation in human
Hatada, I., Fukasawa, M., Kimura, M., Morita, S., Yamada, K., Yoshikawa, T., Yamanaka, S., Endo, C., Sakurada, A., Sato, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209331 · Cited by 147
“Aberrant hypermethylation is known to inactivate tumour suppressor genes (Baylin et al., 1997; Ushijima, 2005).”
BackgroundSelf-citationWatanabe, Y., Kim, H. S., Castoro, R. J., Chung, W., Estecio, M. R., Kondo, K., Guo, Y., Ahmed, S., Toyota, M., Itoh, F., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.085 · Cited by 147
Trougakos, I. P. (2013) · Gerontology · doi:10.1159/000351207 · Cited by 142
Takeshima, H., Yamashita, S., Shimazu, T., Niwa, T., & Ushijima, T. (2009) · Genome Research · doi:10.1101/gr.093310.109 · Cited by 147
Self-citationGenetic and epigenetic silencing of the beclin 1gene in sporadic breast tumors
Li, Z., Chen, B., Wu, Y., Jin, F., Xia, Y., & Liu, X. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-98 · Cited by 146
“Because aberrant cytosine methylation within 5' end of tumor suppressor genes is commonly observed in cancer cells [23,24], beclin 1 was likely a candidate gene for epigenetic silencing.”
BackgroundAnalysis of Fecal DNA Methylation to Detect Gastrointestinal Neoplasia
Nagasaka, T., Tanaka, N., Cullings, H. M., Sun, D.-S., Sasamoto, H., Uchida, T., Koi, M., Nishida, N., Naomoto, Y., Boland, C. R., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp265 · Cited by 128
Okada, S., Morinobu, S., Fuchikami, M., Segawa, M., Yokomaku, K., Kataoka, T., Okamoto, Y., Yamawaki, S., Inoue, T., Kusumi, I., et al. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.02.002 · Cited by 125
“In terms of biomarker identification, the fact that methylation is closely associated with a specific pathological condition is thought to be important, even if methylation does not induce gene silencing (Ushijima, 2005).”
BackgroundThe presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae
Nakajima, T., Yamashita, S., Maekita, T., Niwa, T., Nakazawa, K., & Ushijima, T. (2008) · International Journal of Cancer · doi:10.1002/ijc.24018 · Cited by 136
Self-citationKreth, S., Thon, N., Eigenbrod, S., Lutz, J., Ledderose, C., Egensperger, R., Tonn, J. C., Kretzschmar, H. A., Hinske, L. C., & Kreth, F. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017156 · Cited by 122
“As MSP and bisulfite sequencing do not cover all possible CpG sites of the MGMT promoter, it cannot be excluded that omissions of functionally relevant CpG sites may have partly accounted for the detected discrepancies [27].”
BackgroundReprimo as a Potential Biomarker for Early Detection in Gastric Cancer
Bernal, C., Aguayo, F., Villarroel, C., Vargas, M. F., Díaz, I., Ossandon, F. J., Santibáñez, E., Palma, M., Aravena, E., Barrientos, C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4522 · Cited by 124
“Methylation abnormalities have been detected in blood or sputum of patients with lung cancer, in serum or plasma of head and neck cancers, in ductal lavage fluid of breast cancer, and in urine from patients with prostate and bladder cancer (7).”
BackgroundInfluentialMammalian DNA methyltransferases.
Siedlecki, P. S., & Zielenkiewicz, P. (2006) · Acta Biochimica Polonica · doi:10.18388/abp.2006_3337 · Cited by 122
“In human cancers promoter hypermethylation is at least as common as mutations causing disruption of tumour suppressor genes (Ushijima, 2005).”
BackgroundDNA methylation patterns in lung carcinomas
Pfeifer, G. P., & Rauch, T. A. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.02.008 · Cited by 128
“Identification of methylated CpG islands in easily accessible biological materials such as serum, sputum or urine has the potential to be useful for the early diagnosis of lung cancer and other malignancies [11-13].”
Lung Cancer Epigenetics: Emerging Biomarkers
Balgkouranidou, I., Liloglou, T., & Lianidou, E. S. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.12.111 · Cited by 126
Aberrant DNA methylation in contrast with mutations
Ushijima, T., & Asada, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01434.x · Cited by 125
Self-citationThe role of 5-hydroxymethylcytosine in human cancer
Pfeifer, G. P., Xiong, W., Hahn, M. A., & Jin, S. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1896-7 · Cited by 144
“for the prediction of treatment responses or the survival of cancer patients (Laird 2003; Ushijima 2005).”
The next innovation cycle in toxicogenomics: Environmental epigenetics
Reamon-Buettner, S. M., MUTSCHLER, V., & Borlak, J. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.01.003 · Cited by 129
Carcinogenic mechanisms of endometrial cancer: Involvement of genetics and epigenetics
Banno, K., Yanokura, M., Iida, M., Masuda, K., & Aoki, D. (2014) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.12442 · Cited by 132
“DNA methylation in CpG islands, which are regions dense with CpG sites, in promoters upstream of gene transcription start sites is critical in gene expression.(55) If the DNA in this region is not methylated, a nucleosome does not form and transcription occurs, while methylation of the same DNA allows nucleosome forma…”
BackgroundKim, Y., Yoon, H. Y., Kim, J. S., Kang, H. W., Min, B.-D., Kim, S., Ha, Y., Kim, I. Y., Ryu, K. H., Lee, S., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28121 · Cited by 110
“However, the identification of bona fide candidate methylation markers that have clinical relevance requires rigorous selection criteria, confirmation of the methylation status and gene expression levels in human tissues, and comparison with clinicopathological parameters or disease outcomes.(6) For these reasons, DNA…”
BackgroundTumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1
Karlgren, M., Gomez, A. V., Stark, K., Svärd, J., Rodríguez‐Antona, C., Oliw, E. H., Bernal, M. L., y Cajal, S. R., Johansson, I., & Ingelman‐Sundberg, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.200 · Cited by 115
Epigenetic diagnostics of cancer — the application of DNA methylation markers
Paluszczak, J., & Baer‐Dubowska, W. (2006) · Journal of Applied Genetics · doi:10.1007/bf03194647 · Cited by 114
“Relevant techniques have been described elsewhere (Cottrell 2004; Ushijima 2005).”
BackgroundMethodTost, J. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-522-0_1 · Cited by 114
“of the promoter that is often—but not necessarily—spanning the transcription start site becomes hypermethylated, the expression of the associated gene is modified [38].”
BackgroundWu, G., Guo, Z., Chang, X., Kim, M. S., Nagpal, J. K., Liu, J., Mäki, J. M., Kivirikko, K. I., Ethier, S. P., Trink, B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0012 · Cited by 116
“Second, the methylation genes could serve as potential DNA markers for cancer diagnosis or even early detection of cancer (6).”
BackgroundMicroarray analysis of promoter methylation in lung cancers
Fukasawa, M., Kimura, M., Morita, S., Matsubara, K., Yamanaka, S., Endo, C., Sakurada, A., Sato, M., Kondo, T., Horii, A., et al. (2006) · Journal of Human Genetics · doi:10.1007/s10038-005-0355-4 · Cited by 106
“However in most cases methylation outside promoter regions do not repress gene transcription (Ushijima 2005).”
BackgroundThe potential role of epigenomic dysregulation in complex human disease
Hatchwell, E., & Greally, J. M. (2007) · Trends in Genetics · doi:10.1016/j.tig.2007.08.010 · Cited by 115
Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary
Morán, S., Martínez‐Cardús, A., Boussios, S., & Esteller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.97 · Cited by 109
Ai, L., Kim, W.-J., Demircan, B., Dyer, L. M., Bray, K. J., Skehan, R. R., Massoll, N. A., & Brown, K. D. (2008) · Carcinogenesis · doi:10.1093/carcin/bgm280 · Cited by 116
Silencing of the UCHL1 gene in human colorectal and ovarian cancers
Okochi‐Takada, E., Nakazawa, K., Wakabayashi, M., Mori, A., Ichimura, S., Yasugi, T., & Ushijima, T. (2006) · International Journal of Cancer · doi:10.1002/ijc.22025 · Cited by 101
“To make a genome-wide screening for genes silenced by their promoter methylation, various technologies have been developed.(11) Among these technologies, the cDNA microarray analysis of cells before and after treatment of cells with a demethylating agent (5-aza-20-deoxycytidine; 5-azadC) (chemical genomic screening) i…”
BackgroundSelf-citationLukes, S. (1985) · Dialnet (Universidad de la Rioja) · Cited by 154
Yin, X., Xiang, T., Li, L., Su, X., Shu, X., Luo, X., Huang, J., Yuan, Y., Peng, W., Oberst, M. D., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3399 · Cited by 108
“Future study of circulating methylated DACT1 in serum or in combination with other methylated TSGs may be performed for the detection of breast cancer [5,33,34].”
BackgroundKalari, S. K., Jung, M., Kernstine, K. H., Takahashi, T., & Pfeifer, G. P. (2012) · Oncogene · doi:10.1038/onc.2012.362 · Cited by 92
Kim, M., Jang, H.-R., Kim, J., Noh, S.-M., Song, K.-S., Cho, J.-S., Jeong, H. Y., Norman, J. C., Caswell, P. T., Kang, G. H., et al. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm291 · Cited by 96
Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancerPreprint
Matsumura, N., Huang, Z., Mori, S., Baba, T., Fujii, S., Konishi, I., Iversen, E. S., Berchuck, A., & Murphy, S. K. (2010) · Genome Research · doi:10.1101/gr.108803.110 · Cited by 95
“Treatment of cells with inhibitors of DNA methyltransferase activity is expected to result in increased expression of genes that are silenced by DNA methylation, which can be comprehensively detected using microarrays (Ushijima 2005).”
BackgroundIdentification of genes epigenetically silenced by CpG methylation in human gastric carcinoma
Jee, C. D., Kim, M. A., Jung, E. J., Kim, J., & Kim, W. H. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.027 · Cited by 94
“Generally, tumour cells have promoter methylation patterns that differ from those of normal cells.(7) Furthermore, recently, DNA methylation has emerged as promising biomarker for cancer detection(8), and a number of genes, e.”
BackgroundElectrochemical DNA Methylation Detection for Enzymatically Digested CpG Oligonucleotides
Kato, D., Goto, K., Fujii, S., Takatsu, A., Hirono, S., & Niwa, O. (2011) · Analytical Chemistry · doi:10.1021/ac201761c · Cited by 95
Wrzeszczyński, K. O., Varadan, V., Byrnes, J., Lum, E., Kamalakaran, S., Levine, D. A., Dimitrova, N., Zhang, M. Q., & Lucito, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028503 · Cited by 96
“chromosomal abnormalities and epigenetic variations [1,2].”
Epigenetic Silencing of the Tumor Suppressor Cystatin M Occurs during Breast Cancer Progression
Ai, L., Kim, W.-J., Kim, T., Fields, C. R., Massoll, N. A., Robertson, K. D., & Brown, K. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0576 · Cited by 98
“Because aberrant cytosine methylation within CpG islands that encompass both the 5¶ flanking region and the transcriptional start site is commonly observed in cancer cell genomes (41, 42), the architecture of the CST6 gene makes this gene a likely candidate for epigenetic silencing.”
Lewandowska, J., & Bartoszek, A. (2011) · Mutagenesis · doi:10.1093/mutage/ger019 · Cited by 92
Epigenetics of Cancer Progression
Vucic, E. A., Brown, C. J., & Lam, W. L. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.2.215 · Cited by 98
Fu, D.-Y., Wang, Z.-M., Li-Chen, Wang, B.-L., Shen, Z., Huang, W., & Shao, Z. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0339-8 · Cited by 93
“Because aberrant cytosine methylation within CpG islands encompassing both the 50 flanking region and the transcriptional start site was commonly observed in cancer cell genomes [38, 39], we then analyzed a 420 bp segment of this region (-180 bp to ?240 bp; ATG, ?1) which contains 48 CpG dinucleotides and meets the cr…”
BackgroundNasu, K., Kawano, Y., Tsukamoto, Y., Takano, M., Takai, N., Li, H., Furukawa, Y., Abe, W., Moriyama, M., & Narahara, H. (2011) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2011.01663.x · Cited by 98
“DNA methylation is chemically stable and can be easily detected from free circulating DNA in a variety of samples, such as serum, menstrual blood, ductal lavage fluids, ascites and urine.(110,111) The identification and establishment of highly specific and sensitive DNA methylation biomarkers of endometriosis will pro…”
BackgroundAnalysis of tissue-specific differentially methylated regions (TDMs) in humans
Kitamura, E., Igarashi, J., Morohashi, A., Hida, N., Oinuma, T., Nemoto, N., Song, F., Ghosh, S., Held, W. A., Yoshida, C., et al. (2007) · Genomics · doi:10.1016/j.ygeno.2006.11.006 · Cited by 123
Götze, S., Feldhaus, V., Traska, T., Wolter, M., Reifenberger, G., Tannapfel, A., Kuhnen, C., Martin, D., Müller, O., & Sievers, S. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-447 · Cited by 91
“A variety of methods for the genome-wide screening of methylation differences between tumor and normal cells have been established [13] and many aberrantly methylated genes have been identified in different tumor types [14].”
Background
Metadata
- Authors
- Ushijima, T.
- Affiliations
- National Cancer Center Research Institute (JP)
- Corresponding author
- Ushijima, Toshikazu
- ORCID
- Ushijima, Toshikazu
- Venue
- Nature Reviews Cancer
- Published
- 2005-02-18
- Volume
- 5
- Issue
- 3
- Pages
- 223-231
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1999464755
- Cited by
- 483
- References
- 90
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 9 · 2023: 13 · 2022: 13 · 2021: 4 · 2020: 17 · 2019: 17 · 2018: 9 · 2017: 12 · 2016: 15 · 2015: 25 · 2014: 26 · 2013: 36 · 2012: 30
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Syndromes and Imprinting
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- DNA methylation, epigenetic modifications, cancer, tumor suppressor, diagnostic biomarkers, prognostic factors, CpG islands
- MeSH terms
- DNA, Neoplasm, Genetic Markers, Humans, Neoplasms, Promoter Regions, Genetic, Genes, Tumor Suppressor, Genome, CpG Islands, DNA Methylation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.